Sugi Predict

Sugi Predict / Compounds / SCHEMBL301846

SCHEMBL301846

SCHEMBL301846

O=S(=O)(O)c1cc(Cl)sc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.46
▸ CDK1 P06493 3/20 0.46
▸ CCNB1 P14635 3/20 0.46
▸ CCNA2 P20248 3/20 0.46
▸ CCND1 P24385 3/20 0.46
▸ CDK2 P24941 3/20 0.46
▸ CDK7 P50613 3/20 0.46
▸ CCNH P51946 3/20 0.46
▸ CCNA1 P78396 3/20 0.46
▸ CDK6 Q00534 3/20 0.46
▸ DAO P14920 1/20 0.43
▸ PFKFB3 Q16875 1/20 0.42
▸ S100A9 P06702 4/20 0.41
▸ GSK3B P49841 1/20 0.39
▸ ACLY P53396 1/20 0.39
▸ APP P05067 1/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ KMT2A Q03164 1/20 0.36
▸ SLC6A9 P48067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137127 0.98 PKM (0.50) PKMTDP1CDK1CCNB1CCNA2
SCHEMBL11757841 0.98 PKM (0.50) PKMTDP1CDK1CCNB1CCNA2
Fluoride SCHEMBL27733579 0.98 PKM (0.50) PKMTDP1CDK1CCNB1CCNA2
SCHEMBL11760745 0.98 PKM (0.50) PKMTDP1CDK1CCNB1CCNA2
Hydrochloric Acid SCHEMBL11502738 0.98 PKM (0.50) PKMTDP1CDK1CCNB1CCNA2
SCHEMBL18701658 0.80 PKM (0.34) PKMTDP1CDK1CCNB1CCNA2
SCHEMBL388032 0.79 PKM (0.53) PKMTDP1CDK1CCNB1CCNA2
SCHEMBL18701575 0.78 PKM (0.33) PKMTDP1CDK1CCNB1CCNA2
SCHEMBL29016252 0.78 TAAR1 (0.41) PKMTDP1CDK1CCNB1CCNA2
SCHEMBL18701640 0.78 PKM (0.37) PKMTDP1CDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 — — EP claimed
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 — — US claimed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 — — US claimed
CN-102574804-B Quinolinyloxyphenylsulfonamides MAX PLANCK GESELLSCHAFT 2015-01-07 — — CN claimed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 — — US claimed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 — — US claimed
US-20120214817-A1 UROTENSIN II RECEPTOR ANTAGONISTS MARYANOFF BRUCE E (US) 2012-08-23 — — US claimed
EP-2462117-A1 QUINOLINYLOXYPHENYLSULFONAMIDES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-06-13 — — EP claimed
JP-4851328-B2 — — 2012-01-11 — — JP claimed
US-20100222330-A1 New Compounds BIOVITRUM AB (SE) 2010-09-02 — — US claimed
EP-0946539-B1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 2003-08-13 — — EP claimed
WO-2003055478-A1 GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-10 — — WO claimed
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments SMITHKLINE BEECHAM P.L.C. 2003-04-10 — — US claimed
EP-1276725-A2 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 2003-01-22 — — EP claimed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 — — WO claimed
WO-2002090348-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 — — WO claimed
WO-2001079180-A2 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 2001-10-25 — — WO claimed
CN-1246116-A Sulfonamide derivatives, process for their preparation and their use as medicaments SMITHKLINE BEECHAM PLC (GB) 2000-03-01 — — CN claimed
EP-0946539-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1999-10-06 — — EP claimed
WO-1998027081-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1998-06-25 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments TPMT, MPST, STS PKM 704/4885TDP1 3340/4885CDK1 3033/4885
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS PKM 2121/4885TDP1 784/4885CDK1 233/4885
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS PKM 2121/4885TDP1 784/4885CDK1 233/4885
US-20120214817-A1 UROTENSIN II RECEPTOR ANTAGONISTS UTS2R, PLAUR, BDKRB2 PKM 2999/4885TDP1 3396/4885CDK1 2937/4885
US-20100222330-A1 New Compounds SULT2A1, GPR119, STS PKM 1572/4885TDP1 4016/4885CDK1 3621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.